These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 15988846)

  • 1. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
    Daemmrich A; Krucken G
    Sci Cult (Lond); 2000 Dec; 9(4):505-34. PubMed ID: 15988846
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 4. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 5. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
    Lovell MC
    Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
    [No Abstract]   [Full Text] [Related]  

  • 6. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures.
    Dunbar MM
    Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380
    [No Abstract]   [Full Text] [Related]  

  • 7. [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?].
    Schwarz S; Frölich L; Striebel JP; Hennerici MG
    Dtsch Med Wochenschr; 2007 Jan; 132(3):108-12. PubMed ID: 17219346
    [No Abstract]   [Full Text] [Related]  

  • 8. Fumes from the spleen.
    Paediatr Perinat Epidemiol; 1991 Jul; 5(3):258-60. PubMed ID: 1881836
    [No Abstract]   [Full Text] [Related]  

  • 9. Women in clinical trials: concluding remarks.
    Buc NL
    Food Drug Law J; 1993; 48(2):223-6. PubMed ID: 11653146
    [No Abstract]   [Full Text] [Related]  

  • 10. DdI approval offers second chance.
    Albert SG
    Am Pharm; 1991 Dec; NS31(12):6. PubMed ID: 1763779
    [No Abstract]   [Full Text] [Related]  

  • 11. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 12. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RU-486: legal and policy issues confronting the Food and Drug Administration.
    Muhl C
    J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equitable access to biomedical advances: getting beyond the rights impasse.
    Mariner WK
    Conn Law Rev; 1989; 21(3):571-603. PubMed ID: 11650430
    [No Abstract]   [Full Text] [Related]  

  • 15. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 17. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA approves AIDS drug.
    Am Pharm; 1992 Sep; NS32(9):13-4. PubMed ID: 1332462
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.